Sally Davies, the chief medical officer for England, said global action is needed to fight antibiotic, or antimicrobial, resistance and fill a drug "discovery void" by researching and developing new medicines to treat emerging, mutating infections.
Only a handful of new antibiotics have been developed and brought to market in the past few decades, and it is a race against time to find more, as bacterial infections increasingly evolve into "superbugs" resistant to existing drugs. Read more...
MAP: 42 States Have "Nightmare Bacteria" | Mother Jones
The news on antibiotics just keeps getting worse. In the past decade, methicillin-resistant staph aureus—better-known as MRSA—and clostridium difficile ("C. diff" for short) emerged as poster-bugs for antibiotic-resistance. This week, the Centers for Disease Control trumpeted alarming findings about another group of lethal, antibiotic-resistant microbes that has spread in recent years to hospitals across the country.
These "nightmare bacteria"—as CDC director Dr. Tom Frieden dubbed them this week—are called "carbapenem-resistant enterobacteriaceae," or CRE. In healthy people, dozens of enterobacteria species live in the digestive system and pose no threat. In hospital patients with weak immune systems, however, they can cause devastating infections, especially when they acquire resistance to the antibiotics known as carbapenems. These drugs have long served as the treatment of last resort for enterobacterial infections resistant to other antibiotics.